University of Kansas

Hylapharm, LLC

Jordan Hunt

Laird Forrest

Daniel J Aires

Shuang Cai

Ti Zhang

Ryan Moulder

Heather Wilkins

Ruolin Lu

Peter Kleindl

Russell Swerdlow

Eli Michaelis

Chad E Groer

Chad Groer

The present technology is directed to TLR7 and TLR8 agonist compounds, compositions, and methods of using the same for the treatment of cancers and as vaccine adjuvants.

Imidazoquinoline compounds and prodrugs thereof

Compounds, compositions, and methods related to bioenergetic metabolism are provided. The compounds and compositions are suited to promote bioenergetic processes including cellular respiration and glycolytic flux and may be used to treat mitochondrial disorders, neurodegenerative diseases (such as Alzheimer's disease (AD), Parkinson's disease, and/or amyotrophic lateral sclerosis), multiple sclerosis, and/or epilepsy.

Bioenergetically active esters for health and disease

Provided are platinum(IV) compounds of Formula I or pharmaceutically acceptable salts thereof. Also provided are compositions including such compounds as well as methods of using the same.

Platinum(IV) conjugates and methods of use

Compounds, compositions, and methods related to bioenergetic metabolism are provided. The compounds and com positions are suited to promote bioenergetic processes including cellular respiration and glycolytic flux and may be used to treat mitochondrial disorders, neurodegenerative diseases (such as Alzheimer's disease (AD), Parkinson's disease, and/or amyotrophic lateral sclerosis), multiple sclerosis, and/or epilepsy.

Growing community of inventors

Lawrence, KS, United States of America

Jordan Hunt